4.7 Article

Light-triggered polymeric prodrug and nano-assembly for chemo-photodynamic therapy and potentiate immune checkpoint blockade immunotherapy for hepatocellular carcinoma

Journal

MATERIALS & DESIGN
Volume 225, Issue -, Pages -

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.matdes.2022.111457

Keywords

Hepatocellular carcinoma; Light-triggered prodrug; Immune checkpoint blockade; Photodynamic therapy; Paclitaxel; Immunotherapy

Ask authors/readers for more resources

Immune checkpoint blockade therapy is a promising approach for hepatocellular carcinoma treatment, but many patients do not respond due to low tumor antigen exposure and the immunosuppressive tumor microenvironment. Combination chemo-photodynamic therapy can enhance the effectiveness of immune checkpoint blockade therapy in eliminating tumors and boosting anti-tumor immune responses.
Immune checkpoint blockade (ICB) therapy has emerged as a promising approach for the treatment of hepatocellular carcinoma (HCC), especially for advanced and metastatic tumors. However, many HCC patients do not respond due to low tumor antigen exposure and the highly immunosuppressive tumor microenvironment (ITM). Chemotherapy and photodynamic therapy are considered to be effective meth-ods for eliciting anti-tumor immune responses. Here, we developed a light-triggered nanoplatform Ce6@PMTKP for combination chemo-photodynamic therapy and the potentiation of ICB therapy. The Ce6@PMTKP micelles entrapped Ce6 for photodynamic therapy, while PMTKP contains the ROS-sensitive paclitaxel (PTX) polymeric prodrug for chemotherapy. The Ce6@PMTKP micelles showed excel-lent tumor accumulation and light-triggered drug release. Compared with chemotherapy or photody-namic therapy alone, the combination therapy mediated by Ce6@PMTKP was found to be more effective in the elimination of tumors, induction of immunogenic cell death, and the promotion of den-dritic cell maturation and cytotoxic T lymphocytes infiltration, thus mitigating ITM immunosuppression. When combined with anti-PD-L1 immunotherapy, the Ce6@PMTKP micelles induced complete regres-sion of primary tumors and effectively inhibited distant metastatic tumors by enhancing anti-tumor immune responses. (c) 2022 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http:// creativecommons.org/licenses/by-nc-nd/4.0/).

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available